The goal of this K24 Mid-Career Clinician-Scientist proposal is to allow the Candidate, Dr. Edward Nunes, to continue to expand his program of research and research mentorship in the field of drug abuse treatment development. The Candidate's research program focuses on two related themes, the treatment of co-occurring psychopathology in substance dependent patients, and the development of combinations of behavioral and pharmacological treatments for drug dependence. Major activities and accomplishments have included a series of studies examining the efficacy of antidepressant medications for treatment of opioid, cocaine, and alcohol dependent patients with depression, projects applying advances in behavioral therapies to naltrexone maintenance for opioid dependence and to treatment of depression among methadone maintained patients, applications of behavioral therapy to enhance the design of cocaine medications development trials, and multi-site effectiveness trials in the NIDA Clinical Trials Network. Through collaborations and the work of colleagues Dr. Nunes has, and continues to mentor, his agenda has expanded to examine structured psychiatric diagnostic methods, HIV risk reduction, and other co-occurring psychopathology including attention deficit hyperactivity disorder, impulsive aggression, post-traumatic stress disorder, pathological gambling, neuropsychological functioning, and childhood psychopathology and risk for drug dependence. Over the course of the proposed K24 Dr. Nunes will serve as Principle Investigator on a Center Project, two R01s, and the Long Island Node of the Clinical Trials Network, and as Co-l, Sponsor, or Co-Sponsor on funded projects of junior colleagues and mentored K awards. In particular the K24 will free Dr. Nunes'time and provide resources to pursue the development of new initiatives and collaborations in treatment research and to create opportunities in patient-oriented research for junior colleagues. The mentoring plan will serve young investigators at three main levels, 1) junior faculty with early or emerging independent research programs many of whom Dr. Nunes has mentored since fellowship or during K awards, 2) three current K23 awardees for whom Dr. Nunes serves as Sponsor, and three current (or anticipated) K23 or K01 awardees for whom he serves as Co-Sponsor or Consultant, and 3) Post doctoral fellows in clinical research in the Department's NIDA funded T32 research fellowship program. In addition Dr. Nunes will seek to foster independent research initiatives and collaborations involving the clinical leadership of community-based treatment programs participating in the Clinical Trials Network. The ultimate goals are to improve the treatment of drug dependent patients through clinical research and to help foster the next generation of clinician-researchers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24DA022412-03
Application #
7667756
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Aklin, Will
Project Start
2007-05-01
Project End
2012-04-30
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
3
Fiscal Year
2009
Total Cost
$174,841
Indirect Cost
Name
Columbia University (N.Y.)
Department
Psychiatry
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Campbell, Aimee N C; Barbosa-Leiker, Celestina; Hatch-Maillette, Mary et al. (2018) Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict 27:465-470
Aharonovich, Efrat; Campbell, Aimee N C; Shulman, Matisyahu et al. (2018) Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders. J Addict Med 12:99-106
Levin, Frances R; Choi, C Jean; Pavlicova, Martina et al. (2018) How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. Drug Alcohol Depend 188:135-140
Nunes, Edward V; Gordon, Michael; Friedmann, Peter D et al. (2018) Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. J Subst Abuse Treat 85:49-55
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Friedmann, Peter D; Wilson, Donna; Nunes, Edward V et al. (2018) Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? J Subst Abuse Treat 85:61-65
Chen, Donna T; Ko, Tomohiro M; Allen, Ashleigh A et al. (2018) Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. J Empir Res Hum Res Ethics 13:160-172
Shulman, Matisyahu; Campbell, Aimee; Pavlicova, Martina et al. (2018) Cognitive functioning and treatment outcomes in a randomized controlled trial of internet-delivered drug and alcohol treatment. Am J Addict 27:509-515
Trivedi, Madhukar H; Greer, Tracy L; Rethorst, Chad D et al. (2017) Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry 78:1075-1082
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80

Showing the most recent 10 out of 115 publications